Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2107 Target Snapshot

C-X-C chemokine receptor type 4 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,853Compounds
549Assays
6Approved Drugs
1,996.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

C-X-C chemokine receptor type 4 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P61073. Start with neoplasm, then reuse UniProt P61073 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt P61073 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 6 linked drugs
Open source guide
Disease program
neoplasm

C-X-C chemokine receptor type 4 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 6 linked drugs remain visible in the same block.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include BALIXAFORTIDE, MAVORIXAFOR, MOTIXAFORTIDE, MSX-122. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 6 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats C-X-C chemokine receptor type 4 as ChEMBL target CHEMBL2107, mapped to UniProt P61073. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
C-X-C chemokine receptor type 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2107
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P61073
C-X-C chemokine receptor type 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether C-X-C chemokine receptor type 4 is the right protein anchor across sources, using UniProt P61073 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as approved-linked support. It currently carries 6 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameC-X-C chemokine receptor type 4
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP61073
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelC-X-C chemokine receptor type 4
UniProt AccessionP61073
Component TypeProtein
Sequence Length352 aa

C-X-C chemokine receptor type 4

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as C-X-C chemokine receptor type 4, mapped to UniProt P61073. Sequence length is 352 aa.

Mapped IDP61073
Review nameC-X-C chemokine receptor type 4
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

C-X-C chemokine receptor type 4 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
neoplasm
6 linked drugs · 6 direct · 6 efficacy
Linked drugBALIXAFORTIDE
Linked drugMAVORIXAFOR
Linked drugMOTIXAFORTIDE
Linked drugMSX-122
Approved-linked Approved
multiple myeloma
5 linked drugs · 5 direct · 5 efficacy
Linked drugBALIXAFORTIDE
Linked drugBURIXAFOR
Linked drugMOTIXAFORTIDE
Linked drugPLERIXAFOR
Approved-linked Approved
non-Hodgkins lymphoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugBURIXAFOR
Linked drugMOTIXAFORTIDE
Linked drugPLERIXAFOR
Approved-linked Approved
acute lymphoblastic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugPLERIXAFOR
Approved-linked Approved
childhood cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugPLERIXAFOR
Approved-linked Approved
Hematopoietic Stem Cell Transplantation
1 linked drug · 1 direct · 1 efficacy
Linked drugPLERIXAFOR
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include BALIXAFORTIDE, MAVORIXAFOR, MOTIXAFORTIDE, MSX-122. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

6
Approved
1
Phase III
Assay Mix

Activity Type Distribution

IC501,550.0
KI140.0
EC50300.0
KD6.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4751485 10.7 IC50 0.02 Preclinical
CHEMBL5612607 9.92 EC50 0.12 Preclinical
CHEMBL5611972 9.72 EC50 0.19 Preclinical
CHEMBL5612623 9.72 EC50 0.19 Preclinical
CHEMBL5613902 9.62 EC50 0.24 Preclinical
CHEMBL4799439 9.6 IC50 0.25 Preclinical
CHEMBL237830 9.52 EC50 0.3 Preclinical
CHEMBL237830 9.52 IC50 0.3 Preclinical
CHEMBL1242210 9.47 IC50 0.34 Preclinical
CHEMBL2372985 9.4 EC50 0.4 Preclinical
Distribution

pChEMBL Value Distribution

117
5.0
130
5.5
180
6.0
235
6.5
260
7.0
201
7.5
138
8.0
49
8.5
28
9.0
8
9.5
pChEMBL
Approved Drugs

Approved Drugs

MAVORIXAFOR
CHEMBL518924
Approved 2024
Properties Compare Identifier
PLERIXAFOR
CHEMBL18442
Approved 2008
Properties Compare Identifier
ZALCITABINE
CHEMBL853
Approved 1992
Properties Compare Identifier
Assay Landscape

Assay Landscape

549
Total Assays
580
Tested Compounds
2
Assay Types
Binding — 378 assays, 580 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 313 521 6.8
single protein format 63 58 7.0
assay format 1 1 4.2
cell membrane format 1 0 —
Functional — 171 assays, 556 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 150 528 6.8
assay format 19 27 6.9
single protein format 2 1 5.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine